工程化益生菌用于肿瘤靶向联合化学免疫治疗
Engineered probiotics for tumor-targeted combination chemoimmunotherapy.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
索拉非尼处理的 Th9 细胞在肺转移中表现出优越的抗肿瘤效果
英文原题：Sorafenib-treated Th9 cells exhibit superior anti-tumor effect in lung metastasis.
查看英文原题
Sorafenib-treated Th9 cells exhibit superior anti-tumor effect in lung metastasis.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
肺是肿瘤转移的第二常见器官，治疗选择有限且治疗结果令人失望。辅助性T细胞9（Th9）已被报道可有效清除实体瘤，并表现出优于辅助性T细胞1（Th1）和辅助性T细胞17（Th17）细胞的抗肿瘤特性，这使其成为针对肺转移的过继性细胞疗法（ACT）的潜在候选者。然而，Th9细胞如何在体外大规模扩增尚不清楚。在此，我们发现索拉非尼（Sora）可通过ERK信号通路提高体外Th9的扩增效率。此外，经Sora处理的Th9细胞在肺转移小鼠模型中通过重塑肿瘤免疫微环境表现出优越的抗肿瘤效果。因此，我们的发现提供了一种潜在的体外扩增Th9细胞以治疗肺转移的方法。
展开英文摘要原文
The lung is the second most common organ of tumor metastasis, with limited treatment options and disappointing treatment outcomes. T helper 9 (Th9) cells have been reported to be effective in the elimination of solid tumors and exhibit superior antitumor properties to T helper 1 (Th1) and T helper 17 (Th17) cells, which makes a potential candidate for Adoptive cell therapy (ACT) against lung metastasis.
However, how Th9 cells can be massively expanded in vitro is not clear.
Here, we found Sorafenib (Sora) can increase the efficiency of Th9 in vitro through ERK signaling.
In addition, Sora-treated Th9 cells exhibit superior anti-tumor effects by reshaping tumor immune microenvironment in lung metastasis mice model.
Thus, our findings provide a potential method to expand Th9 cells in vitro for lung metastasis treatment.
论文信息
- 作者
- Yuan F、Wang H、Wang S、Wang J、Li J、Shen Y、Lin J、Guo J
- 第一作者单位
- Clinical Laboratory, Affiliated Xiangshan Hospital of Wenzhou Medical University, Ningbo, 315700, Zhejiang, China.China
- 通讯作者单位
- Department of Breast Surgery, Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University, Hangzhou, 310006, Zhejiang, China. m18758114522@163.com.China
- 期刊
- Scientific reports2025 Aug 7
- 原文标识
- PubMed 40775250 · DOI 10.1038/s41598-025-11450-8
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →